Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BCRX Stock Forecast 2026-2027
$6.66
Current Price
$1.40B
Market Cap
Buy 9
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to BCRX Price Targets
+380.5%
To High Target of $32.00
+192.8%
To Median Target of $19.50
+35.1%
To Low Target of $9.00
BCRX Price Momentum
-6.1%
1 Week Change
-10.1%
1 Month Change
-10.6%
1 Year Change
-14.6%
Year-to-Date Change
-41.1%
From 52W High of $11.31
+11.0%
From 52W Low of $6.00
📊 TOP ANALYST CALLS
Did BCRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if BioCryst is one of their latest high-conviction picks.
Latest BCRX Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, BCRX has a bullish consensus with a median price target of $19.50 (ranging from $9.00 to $32.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $6.66, the median forecast implies a 192.8% upside. This outlook is supported by 9 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andrew S. Fein at HC Wainwright & Co., projecting a 380.5% upside. Conversely, the most conservative target is provided by Gena Wang at Barclays, suggesting a 35.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BCRX Analyst Ratings
9
Buy
1
Hold
0
Sell
BCRX Price Target Range
Low
$9.00
Average
$19.50
High
$32.00
Current: $6.66
Latest BCRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BCRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 15, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $32.00 |
| Nov 5, 2025 | Citizens | Jonathan Wolleben | Market Outperform | Maintains | $25.00 |
| Nov 4, 2025 | Barclays | Gena Wang | Equal-Weight | Maintains | $9.00 |
| Nov 4, 2025 | Needham | Serge Belanger | Buy | Maintains | $18.00 |
| Oct 15, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $27.00 |
| Oct 15, 2025 | Needham | Serge Belanger | Buy | Maintains | $20.00 |
| Oct 15, 2025 | TD Cowen | Stacy Ku | Buy | Reinstates | $30.00 |
| Oct 15, 2025 | Cantor Fitzgerald | Steven Seedhouse | Overweight | Maintains | $26.00 |
| Aug 4, 2025 | Needham | Serge Belanger | Buy | Maintains | $17.00 |
| Jul 1, 2025 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $15.00 |
| Jun 30, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $18.00 |
| Jun 30, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $13.00 |
| Jun 27, 2025 | Needham | Serge Belanger | Buy | Reiterates | $17.00 |
| Jun 25, 2025 | Needham | Serge Belanger | Buy | Reiterates | $17.00 |
| May 7, 2025 | Barclays | Gena Wang | Equal-Weight | Maintains | $11.00 |
| May 6, 2025 | Needham | Serge Belanger | Buy | Maintains | $17.00 |
| May 6, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $30.00 |
| May 6, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $13.00 |
| May 6, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $13.00 |
| Apr 29, 2025 | Cantor Fitzgerald | Steven Seedhouse | Overweight | Initiates | $20.00 |
BioCryst Pharmaceuticals Inc. (BCRX) Competitors
The following stocks are similar to BioCryst based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BioCryst Pharmaceuticals Inc. (BCRX) Financial Data
BioCryst Pharmaceuticals Inc. has a market capitalization of $1.40B with a P/E ratio of -15.5x. The company generates $599.82M in trailing twelve-month revenue with a -1.5% profit margin.
Revenue growth is +36.1% quarter-over-quarter, while maintaining an operating margin of +18.6% and return on equity of +18.7%.
Valuation Metrics
Market Cap
$1.40B
Enterprise Value
$1.87B
P/E Ratio
-15.5x
PEG Ratio
0.1x
Price/Sales
2.3x
Growth & Margins
Revenue Growth (YoY)
+36.1%
Gross Margin
+98.6%
Operating Margin
+18.6%
Net Margin
-1.5%
EPS Growth
+36.1%
Financial Health
Cash/Price Ratio
+15.2%
Current Ratio
1.9x
Debt/Equity
-1.8x
ROE
+18.7%
ROA
+10.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
BioCryst Pharmaceuticals Inc. (BCRX) Business Model
About BioCryst Pharmaceuticals Inc.
What They Do
Develops oral medicines for rare diseases.
Business Model
The company focuses on the discovery and development of small-molecule therapies for rare diseases, generating revenue through the commercialization of its innovative products. By addressing unmet medical needs, BioCryst positions itself to capture a niche market where competition is limited, thus enhancing its profitability.
Additional Information
BioCryst operates within the rapidly growing biotechnology sector, known for its potential in medical advancements. Its expertise in structure-based drug design allows the company to create targeted solutions in immunology and hematology, making it a significant contributor to healthcare improvements for patients with few treatment options.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
580
CEO
Mr. Jon P. Stonehouse
Country
United States
IPO Year
1994
Website
www.biocryst.comBioCryst Pharmaceuticals Inc. (BCRX) Latest News & Analysis
Latest News
Quick Summary
Preliminary 2025 ORLADEYO net revenue is projected at $563 million, reflecting a 43% year-over-year increase, excluding European revenue.
Why It Matters
The 43% year-over-year growth in ORLADEYO's net revenue signals strong demand and potential market expansion, which could positively impact the company's stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BioCryst Pharmaceuticals, Inc. (BCRX) recently presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its latest developments and strategic direction.
Why It Matters
BioCryst's presentation at a major healthcare conference signals potential growth opportunities, strategic direction, and investor interest, impacting stock performance and market perception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Former Louisiana Attorney General Charles C. Foti, Jr. has been mentioned in a news release dated January 7, 2026, based in New York and New Orleans. Further details were not provided.
Why It Matters
The mention of a former Attorney General indicates potential legal developments or regulatory changes that could impact local businesses, influencing market dynamics in those regions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
BioCryst Pharmaceuticals granted 18,300 restricted stock units to a new employee on January 2, 2026, as part of their compensation strategy, compliant with Nasdaq regulations.
Why It Matters
The grant of RSUs indicates BioCryst's commitment to attracting talent, potentially enhancing its growth and innovation, which can positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 1:30 p.m. ET in San Francisco.
Why It Matters
BioCryst Pharmaceuticals' presentation at a major healthcare conference could signal potential advancements, partnership opportunities, or investor interest, impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The FDA has approved BioCryst Pharmaceuticals' oral pellet formulation of its drug for preventing hereditary angioedema attacks in children aged 2 to under 12.
Why It Matters
The FDA's expansion of BioCryst's drug use can boost revenue potential, enhance market position, and positively impact stock performance due to increased growth opportunities in pediatric care.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About BCRX Stock
What is BioCryst Pharmaceuticals Inc.'s (BCRX) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, BioCryst Pharmaceuticals Inc. (BCRX) has a median price target of $19.50. The highest price target is $32.00 and the lowest is $9.00.
Is BCRX stock a good investment in 2026?
According to current analyst ratings, BCRX has 9 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.66. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BCRX stock?
Wall Street analysts predict BCRX stock could reach $19.50 in the next 12 months. This represents a 192.8% increase from the current price of $6.66. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is BioCryst Pharmaceuticals Inc.'s business model?
The company focuses on the discovery and development of small-molecule therapies for rare diseases, generating revenue through the commercialization of its innovative products. By addressing unmet medical needs, BioCryst positions itself to capture a niche market where competition is limited, thus enhancing its profitability.
What is the highest forecasted price for BCRX BioCryst Pharmaceuticals Inc.?
The highest price target for BCRX is $32.00 from Andrew S. Fein at HC Wainwright & Co., which represents a 380.5% increase from the current price of $6.66.
What is the lowest forecasted price for BCRX BioCryst Pharmaceuticals Inc.?
The lowest price target for BCRX is $9.00 from Gena Wang at Barclays, which represents a 35.1% increase from the current price of $6.66.
What is the overall BCRX consensus from analysts for BioCryst Pharmaceuticals Inc.?
The overall analyst consensus for BCRX is bullish. Out of 15 Wall Street analysts, 9 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $19.50.
How accurate are BCRX stock price projections?
Stock price projections, including those for BioCryst Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 2:16 AM UTC